ViaCyte formerly Novocell is a preclinical therapeutic company focused on diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrates that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Current Team (3)Update
Funding Rounds (6) - $97.6MUpdate
The California Institute for Regenerative Medicine (The Institute or CIRM) was established in...
Venture capital subsidiary
Oldest investment firms
Pacific Horizon Ventures is a Seattle-based venture capital firm, with national presence, focused...
Asset Management Company is a Silicon Valley venture capital firm. Since 1965, the company has...
DFJ Portage Ventures invests anywhere from $500,000 to over $20 million in seed and early stage...
med device, biotech vc
Headland Ventures LP is a Venture Partnership focused on early stage company investing. The...
3550 General Atomics Court
San Diego, CA 92121